---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-24-000120"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:08:13.972618+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Editas Q3 net loss widens to $62.1M; cash runway extended into Q2 2026

## Summary
- Q3 2024 net loss of $62.1M ($0.75/sh) vs $45.0M ($0.55/sh) in Q3 2023; R&D spend up $7.1M.
- Cash, equivalents and securities $265.1M at Sept 30; with DRI $57M upfront totals ~$322.1M.
- In vivo preclinical proof of concept for HBG1/2 editing in HSPCs using targeted LNP achieved.
- Reni-cel partnering process with Moelis & Co underway; 28-patient RUBY update at ASH in December.
- Collaboration revenue fell to $0.1M from $5.3M on prior-year Vor Bio upfront payment.

## SEC filing metadata
- accession: 0001650664-24-000120
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000120/0001650664-24-000120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000120/edit-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-24-000120
- JSON: https://secwatch.observer/filing/0001650664-24-000120.json
- Plain text: https://secwatch.observer/filing/0001650664-24-000120.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.